The foundational Chronic Inflammatory Demyelinating Polyneuropathy Market Data highlights a projected CAGR of 7.3% between 2025 and 2035, confirming the market's accelerated trajectory. This growth rate is noteworthy for a rare disease market, underscoring the high investment return potential driven by chronic treatment needs and the introduction of advanced, high-cost therapies. Furthermore,...